Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Imipramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 14/20 | 0.94 |
| ▸ | SLC6A2 known ✓ | P23975 | 5/20 | 0.94 |
| ▸ | HRH1 | P35367 | 6/20 | 0.94 |
| ▸ | HTR2A | P28223 | 5/20 | 0.94 |
| ▸ | SLC22A1 | O15245 | 4/20 | 0.94 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.94 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.94 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.94 |
| ▸ | DRD2 | P14416 | 4/20 | 0.94 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.94 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.94 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.94 |
| ▸ | HTR2C | P28335 | 4/20 | 0.94 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.94 |
| ▸ | DRD3 | P35462 | 4/20 | 0.94 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.94 |
| ▸ | HTR2B | P41595 | 4/20 | 0.94 |
| ▸ | MTOR | P42345 | 4/20 | 0.94 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.94 |
| ▸ | LMNA | P02545 | 3/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imipramine SCHEMBL17004048 | 0.97 | SLC6A4 (1.00) | SLC6A4HRH1HTR2ASLC6A2SLC22A1 | |
| Imipramine SCHEMBL34282 | 0.97 | SLC6A4 (1.00) | SLC6A4HRH1HTR2ASLC6A2SLC22A1 | |
| Imipramine SCHEMBL29350100 | 0.97 | SLC6A4 (1.00) | SLC6A4HRH1HTR2ASLC6A2SLC22A1 | |
| Imipramine SCHEMBL6118138 | 0.97 | SLC6A4 (1.00) | SLC6A4HRH1HTR2ASLC6A2SLC22A1 | |
| Imipramine SCHEMBL41766 | 0.95 | LMNA (1.00) | SLC6A4HRH1HTR2ASLC6A2SLC22A1 | |
| Imipramine SCHEMBL29040915 | 0.95 | SLC6A4 (0.97) | SLC6A4HRH1HTR2ASLC6A2SLC22A1 | |
| Imipramine SCHEMBL27657924 | 0.95 | SLC6A4 (0.97) | SLC6A4HRH1HTR2ASLC6A2SLC22A1 | |
| Imipramine SCHEMBL41765 | 0.95 | LMNA (1.00) | SLC6A4HRH1HTR2ASLC6A2SLC22A1 | |
| Imipramine SCHEMBL28759733 | 0.95 | LMNA (1.00) | SLC6A4HRH1HTR2ASLC6A2SLC22A1 | |
| Imipramine SCHEMBL15719828 | 0.94 | LMNA (0.97) | SLC6A4HRH1HTR2ASLC6A2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12564596-B2 | Agents and methods for modulating pathogen activity | GRIFFITH UNIVERSITY (AU) | 2026-03-03 | — | — | US | disclosed |
| US-20250235496-A1 | USE OF BELLIDIFOLIN (BEL) AND/OR BEL-CONTAINING EXTRACT IN PREPARATION OF ANTIDEPRESSANT PRODUCT | NORTHWEST INSTITUTE OF PLATEAU BIOLOGY, CAS (CN) | 2025-07-24 | — | — | US | disclosed |
| CN-118986994-A | Agents and methods for modulating pathogen activity | 格里菲斯大学 | 2024-11-22 | — | — | CN | disclosed |
| CN-113164494-B | Agents and methods for modulating pathogen activity | 格里菲斯大学 | 2024-08-27 | — | — | CN | disclosed |
| CN-118078799-A | Application of bellytalinone and/or bellytalinone-containing extract in preparation of antidepressant product | 中国科学院西北高原生物研究所 | 2024-05-28 | — | — | CN | disclosed |
| EP-4295864-A2 | PHENYLPROPIONIC ACID DERIVATIVES FOR MODULATING PATHOGEN ACTIVITY | Research Institute at Nationwide Children's Hospital (US) | 2023-12-27 | — | — | EP | disclosed |
| EP-3856196-B1 | PHENYLPROPIONIC ACID DERIVATIVES FOR MODULATING PATHOGEN ACTIVITY | UNIV GRIFFITH (AU) | 2023-11-15 | — | — | EP | disclosed |
| CN-116973579-A | Combined marker for detecting toxicity recognition capability of liver organoids on compounds and evaluation method | 上海交通大学医学院 | 2023-10-31 | — | — | CN | disclosed |
| US-20210338685-A1 | AGENTS AND METHODS FOR MODULATING PATHOGEN ACTIVITY | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL | 2021-11-04 | — | — | US | disclosed |
| CN-101896161-A | Solid formulations of crystalline compounds | PURDUE RESEARCH FOUNDATION | 2010-11-24 | — | — | CN | disclosed |
| US-20100222311-A1 | SOLID FORMULATIONS OF CRYSTALLINE COMPOUNDS | PURDUE RESEARCH FOUNDATION (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100191475-A1 | METHOD FOR IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF AGENTS WHICH MODULATE ION CHANNEL ACTIVITY | PERSCHKE SCOTT | 2010-07-29 | — | — | US | disclosed |
| US-20090075377-A1 | MOLECULAR INTERACTIONS IN CELLS | ARBOR VITA CORPORATION (US) | 2009-03-19 | — | — | US | disclosed |
| EP-1839222-A2 | A METHOD FOR IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF AGENTS WHICH MODULATE ION CHANNEL ACTIVITY | Novascreen Biosciences (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20070149479-A1 | Nanoparticulate inclusion and charge complex for pharmaceutical formulations | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-06-28 | — | — | US | disclosed |
| WO-2007025767-A2 | NANOPARTICULATE INCLUSION AND CHARGE COMPLEX FOR PHARMACEUTICAL FORMULATIONS | SCHERING AG (DE) | 2007-03-08 | — | — | WO | disclosed |
| WO-2006066219-A2 | A METHOD FOR IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF AGENTS WHICH MODULATE ION CHANNEL ACTIVITY | NOVASCREEN BIOSCIENCES (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20060136140-A1 | Method for identification and functional characterization of agents which modulate ion channel activity | NOVASCREEN BIOSCIENCES | 2006-06-22 | — | — | US | disclosed |
| US-20050282743-A1 | Molecular interactions in cells | ARBOR VITA CORPORATION (US) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12564596-B2 | Agents and methods for modulating pathogen activity | C3AR1, HTR3A, CHRM3 | SLC6A4 700/4885SLC6A2 366/4885HRH1 197/4885 |
| US-20250235496-A1 | USE OF BELLIDIFOLIN (BEL) AND/OR BEL-CONTAINING EXTRACT IN PREPARATION OF ANTIDEPRESSANT PRODUCT | CRH, GAP43, CHRNB3 | SLC6A4 133/4885SLC6A2 182/4885HRH1 1616/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | SLC6A4 2649/4885SLC6A2 804/4885HRH1 1245/4885 |
| US-20210338685-A1 | AGENTS AND METHODS FOR MODULATING PATHOGEN ACTIVITY | C3AR1, HAVCR2, C5AR1 | SLC6A4 4768/4885SLC6A2 4751/4885HRH1 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.